Advertisement
Canada markets open in 24 minutes
  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CAD/USD

    0.7289
    -0.0031 (-0.43%)
     
  • CRUDE OIL

    83.25
    -0.11 (-0.13%)
     
  • Bitcoin CAD

    90,711.29
    -47.15 (-0.05%)
     
  • CMC Crypto 200

    1,434.48
    +10.38 (+0.73%)
     
  • GOLD FUTURES

    2,335.30
    -6.80 (-0.29%)
     
  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     
  • 10-Yr Bond

    4.6480
    +0.0500 (+1.09%)
     
  • NASDAQ futures

    17,706.50
    +99.75 (+0.57%)
     
  • VOLATILITY

    15.81
    +0.12 (+0.76%)
     
  • FTSE

    8,077.62
    +32.81 (+0.41%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • CAD/EUR

    0.6822
    -0.0014 (-0.20%)
     

What Analysts Recommend for Neurocrine Biosciences in April 2018

What Analysts Recommend for Neurocrine Biosciences in April 2018

In April 2018, the US FDA (Food and Drug Administration) notified Neurocrine Biosciences and AbbVie (ABBV) that it would require more time to review additional information associated with the liver function tests provided by AbbVie in addition to it its NDA (new drug application) for Elagolix. The US FDA granted the new PDUFA (Prescription Drug Fee User Act) action date in 3Q18.